Benign Breast Disease and Early Breast Cancer Epidemiology

DelveInsight's "Benign Breast Disease and Early Breast Cancer - Epidemiology Forecast– 2034” report delivers an in-depth understanding of the benign breast disease and early breast cancer, historical and forecasted epidemiology trends in the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• The EU4 (Germany, France, Italy, and Spain), and the United Kingdom
• Japan

Study Period: 2021-2034

Benign Breast Disease and Early Breast Cancer Disease Understanding

Benign Breast Disease and Early Breast Cancer Overview

Benign breast disease is a spectrum of lesions that are frequently discovered on clinical examination, routine imaging, by the patient on self-examination, or due to mastalgia and after appropriate imaging and indicated sampling confirms a benign diagnosis, treatment is directed to symptomatic relief and the patient education without additional surgical management. Benign lesions are more common at younger ages, with benign breast disease beginning to rise in the second decade and peaking between the ages of 40 and 50.

Early Breast Cancer means cancer has not spread beyond the breast or the lymph nodes in the armpit on the same side of the body. So, cancer has not spread to any other part of the body. The number staging system divides breast cancers into different stages. Early breast cancer includes Stage 0, Stage I, and Stage II.

Benign Breast Disease and Early Breast Cancer Diagnosis

The tests and procedures used to diagnose a benign breast condition are often the same as those used to diagnose early breast cancer. The goals of diagnosis are to make sure that the growth or other change detected is benign, determine whether the condition is associated with any increase in cancer risk. Clinical breast examination, diagnostic imaging including x-ray, ultrasound, MRI, and mammography are some tests used for diagnosis. Furthermore, biopsy is also considered for the diagnosis of benign breast disease and early breast cancer.

Benign Breast Disease and Early Breast Cancer Epidemiology

As the Benign Breast Disease and Early Breast Cancer Market is derived using a patient-based model, the benign breast disease and early breast cancer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of breast cancer, total incident cases of benign breast disease and early breast cancer, benign breast disease cases by clinical type, early breast cancer cases by age, and total benign breast disease and early breast cancer patients seeking treatment in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2021 to 2034.

Key Findings

This section provides glimpse of the benign breast disease and early breast cancer epidemiology in the 7MM

Country Wise - Benign Breast Disease and Early Breast Cancer Epidemiology

• In the United States., biopsy-confirmed benign breast disease diagnosis are 4-times more common than invasive breast cancers, affecting ~1 million women annually.
• In the United States, out of approximately 1.6 million breast biopsies, around 75-90% return a diagnosis of benign breast disease including atypical hyperplasia.
• The total incident cases of benign breast disease and early breast cancer in the 7MM comprised approximately 2.9 and 0.5 million respectively in 2022 and are projected to increase during the forecasted period.
• The total number of incident cases of benign breast disease and early breast cancer in the United States were around 1.4 and 0.2 million respectively in 2022.
• The United States contributed to the largest incident population of benign breast disease and early breast cancer, acquiring ~49% of the 7MM followed by EU4 and the UK, and Japan in 2022.
• Among the EU4 countries, Germany accounted for the largest number of benign breast disease cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
• According to DelveInsight estimates, there were around 0.5 million patients seeking treatment for benign breast disease and 0.2 million patients seeking treatment for early breast cancer in the United States in 2022.

Scope of the Report

• The report covers a segment of an executive summary, descriptive overview of benign breast disease and early breast cancer, explaining its causes, signs and symptoms, classification and currently available interventions.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression along with treatment guidelines.
• Additionally, an all-inclusive account of both the current interventions, along with the elaborative profiles of newer surgical options, will have an impact on the current treatment landscape.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM benign breast disease and early breast cancer market.

Report Highlights

• Ten Years Forecast
• 7MM Coverage
• Total Incidence cases of benign breast disease and early breast cancer
• Age-specific cases of early breast cancer

Benign Breast Disease and Early Breast Cancer Report Insights

• Patient Population
• Ten Years Forecast
• 7MM Coverage
• Benign Breast Disease And Early Breast Cancer Epidemiology Segmentation

Key Questions

• What is the disease risk, burden and unmet needs of benign breast disease and early breast cancer?
• What is the historical benign breast disease and early breast cancer patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the UK and Japan?
• What would be the forecasted patient pool of benign breast disease and early breast cancer at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to benign breast disease and early breast cancer?
• Out of the above-mentioned countries, which country would have the highest incident population of benign breast disease and early breast cancer during the study period (2021-2034)?
• At what CAGR the population is expected to grow across the 7MM during the study period (2021-2034)?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the benign breast disease and early breast cancer.
• Quantify patient populations in the global benign breast disease and early breast cancer market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for benign breast disease and early breast cancer in the US, EU4 (Germany, France, Italy, and Spain), and the United Kingdom and Japan.
• The benign breast disease and early breast cancer Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources.   

Stay Updated with us for Recent Articles:- 

• Metastatic HER2-Positive Breast Cancer
• Estrogen Receptor Positive Breast Cancer: Market Outlook
• Global HR+/ HER2- Breast Cancer Market Scenario
• How HR+/ HER2- Breast Cancer Emerging Drugs Will Transform the Market?
• HR-positive/ HER2-negative Breast Cancer Market Insights: Upcoming Therapies and Market Analysis
• Breast Cancer: Understand Your Breasts, Recognize the Symptoms
• Key Facts To Know About Triple-Negative Breast Cancer In The Breast Cancer Awareness Month
• 7 Most Common Myths About Breast Cancer Demystified
• Roche’s HER2-Positive Breast Cancer Treatment Franchise
• Latest DelveInsight Blogs